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OBJECTIVES: The anesthetic gas xenon is reported to preserve hemodynamic stability during general anesthesia.
However, the effects of the gas during shock are unclear. The objective of this study was to evaluate the effect
of Xe on hemodynamic stability and tissue perfusion in a canine model of hemorrhagic shock.
METHOD: Twenty-six dogs, mechanically ventilated with a fraction of inspired oxygen of 21% and anesthetized
with etomidate and vecuronium, were randomized into Xenon (Xe; n= 13) or Control (C; n= 13) groups.
Following hemodynamic monitoring, a pressure-driven shock was induced to reach an arterial pressure of
40 mmHg. Hemodynamic data and blood samples were collected prior to bleeding, immediately after bleeding
and 5, 20 and 40 minutes following shock. The Xe group was treated with 79% Xe diluted in ambient air,
inhaled for 20 minutes after shock.
RESULT: The mean bleeding volume was 44 mL.kg21 in the C group and 40 mL.kg21 in the Xe group.
Hemorrhage promoted a decrease in both the cardiac index (p,0.001) and mean arterial pressure (p,0.001).
These changes were associated with an increase in lactate levels and worsening of oxygen transport variables in
both groups (p,0.05). Inhalation of xenon did not cause further worsening of hemodynamics or tissue
perfusion markers.
CONCLUSIONS: Xenon did not alter hemodynamic stability or tissue perfusion in an experimentally controlled
hemorrhagic shock model. However, further studies are necessary to validate this drug in other contexts.
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& INTRODUCTION
Xenon (Xe) is an inert gas that is present in the
atmosphere at very low concentrations and has potent
hypnotic and analgesic properties that have been known for
several decades (1-4). This anesthetic gas is neither toxic nor
metabolized within the body, as it is quickly eliminated
through the lungs (4-6) and can be used in patients with
impaired renal or hepatic function with minimal or no side
effects (5). In heart failure conditions, a number of
publications have shown that inhaled xenon is an adequate
alternative to other inhaled anesthetics, as it does not
interfere with cardiac contractility, cardiac autonomic
control or vascular tonic regulation (7-11).
However, few studies have evaluated the impact of xenon
on hemodynamics, oxygen transport and tissue perfusion
during circulatory shock (12,13). It is well known that most
inhalational anesthetics used in clinical practice may hinder
hemodynamic responses to shock, either by directly inter-
fering with cardiac function or the vascular contractile
response or by indirectly decreasing sympathetic activity.
Due to the absence of hemodynamic effects caused by
xenon, this gas is a suitable option in severe shock
conditions under which the cardiovascular depressant
effects of anesthesia would further worsen tissue hypoper-
fusion.
The aim of this study was to assess the impact of xenon on
hemodynamics, oxygen transport and tissue perfusion
markers in dogs undergoing severe hemorrhagic shock.
& MATERIALS AND METHODS
This research project was approved by the Ethics
Committee of the Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo (process CAPPesq
655/97) and was funded through a research grant from
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FAPESP (Fundac¸a˜o de Amparo a` Pesquisa do Estado Sa˜o
Paulo; Process 00/10122-6). The study included 26 mixed-
breed dogs weighing between 10 and 20 kg. The study met
the international criteria for animal care and abided by the
rules of COBEA (The Brazilian College of Animal
Experimentation).
Animal preparation and measurements
A clinical veterinarian evaluated the health status of the
animals following their arrival at the laboratory. Food was
withheld from the animals for 12 hours prior to the experi-
ment and free access to water was available at all times.
Following the arrival of the animals to the research laboratory,
a venous line was inserted into one limb using a 20-G Teflon
catheter. General anesthesia was induced using etomidate
(2 mg.kg21), followed by tracheal intubation with an 8.0-mm
ID cuffed cannula. A continuous infusion of etomidate
(50 mg.kg21.min21) and vecuronium (1 mg.kg21.min21) was
initiated to facilitate pressure-controlled ventilation and to
enable the installation of vascular lines and was maintained
throughout the study. Mechanical ventilation was performed
using a Cicero EM (Drager, Lu¨beck, Germany). The inspira-
tory pressure was set at 15 cmH2O and the respiratory rate
was set at 20 breaths per minute. The fraction of inspired
oxygen (FiO2) was set at 21% (room air) in a semi-closed
circuit with a CO2 absorber. Respiratory system compliance;
tidal volume; and peak, plateau and end-expiratory pressures
were directly monitored with the anesthesia equipment after
pneumotachometer calibration.
After the induction of anesthesia, small-bore polyethylene
catheters (P260) were inserted by dissection into both
femoral arteries. One of the arterial catheters was used
exclusively to measure systemic arterial pressure, whereas
the other catheter was used to remove blood and collect
arterial blood samples. The right internal jugular vein was
dissected and a pulmonary artery catheter (Edwards
Lifesciences, Irvine, CA, USA) was inserted. The position
was confirmed by obtaining pulmonary artery pressure
(PAP) and pulmonary artery occlusion pressure (PAOP)
curves. Heart rate, systolic arterial pressure (SAP), diastolic
arterial pressure (DAP), mean arterial pressure (MAP),
mean PAP and PAOP were measured using a multi-
parameter monitor (Viridia 885, Hewlett-Packard, Palo
Alto, CA, USA). All data from the monitor were stored on
a personal computer. Intravascular pressures were com-
puted using disposable transducers (Edwards Lifesciences,
Irvine, CA, USA), which were filled with a 0.9% sodium
chloride solution and zeroed at the mid-axillary line. Mixed
central venous blood samples were collected from the distal
port of the pulmonary artery catheter. Cardiac output (CO)
was measured using the standard thermodilution techni-
que. The measurement was repeated three times and the
average value was divided by body surface area (BSA) to
obtain the cardiac index (CI). Body surface area was
calculated using the following formula: BSA=0.1226
weight2/3. Systemic and pulmonary hemodynamic calcula-
tions, arterial and mixed venous blood oxygen contents
(CaO2 and CvO2), the venous admixture and oxygen
transport variables were calculated using standard equa-
tion. A pulse oximeter probe was applied to the tongue of
the animal and a gas analyzer (Criticare Systems Inc.,
Waukesha, WI, USA) was placed between the endotracheal
cannula and respiratory circuit Y piece to continuously
monitor FiO2 and ETCO2 levels.
Arterial and mixed venous oxygen (PaO2, PvO2), carbon
dioxide (PaCO2, PvCO2) tensions, arterial lactate concentra-
tion and pH were measured using a blood-gas analyzer
(Radiometer ABL Gas Analyzer, Copenhagen, Denmark).
All results were corrected for body temperature. The
bicarbonate concentration, hemoglobin (Hb) concentration
and base excess were also calculated.
Study protocol and data collection
Animals were randomly allocated to the Control or Xenon
group. A random treatment sequence was obtained using
the Stata 11 statistical software (StataCorp, College Station,
TX, USA). The allocation of each animal was enclosed in a
brown numbered envelope and revealed at the start of each
experiment. Following animal preparation, blood samples
Table 1 - Characteristics of the groups.
Control Group Xenon Group p-value
Weight (kg) 15¡2 15¡2 NS
BSA (m2) 0.71¡0.07 0.72¡0.07 NS
Volume removed (ml) 670¡155 602¡156 NS
BSA – body surface area. NS indicates no significant difference between
groups. Data are expressed as the mean¡SD. n = 13 for both the Control
and Xenon groups.
Figure 1 - Differences in the cardiac index (upper panel) and
mean arterial pressure (lower panel) between the Control (open
circles; n=13) and Xenon (closed circles; n =13) groups during
the study. * indicates a significant difference from baseline,
p,0.05. NS indicates no significant difference. The x-axes of the
graphs are not linear, so the curves are not true to scale. Data are
expressed as the mean¡SD.
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and respiratory and hemodynamic data were collected
before the induction of shock, immediately after induction
and 5, 20 and 40 minutes after induction.
The hemorrhagic shock model used in this study is
described elsewhere (14). Briefly, the animals were sub-
jected to continuous bleeding (25 mL.min21) to achieve a
MAP of 40 mmHg. When the MAP reached 40 mmHg,
continuous bleeding was interrupted and small aliquots of
blood were removed to maintain the target pressure for 2
minutes. Individual variations in the total amount of blood
volume lost were not expected to significantly alter the
MAP. Immediately after establishing circulatory shock in
the Experimental group, xenon inhalation was initiated.
First, the breathing circuit was saturated with a specially
prepared gas mixture (White Martins, Sa˜o Paulo, Brazil)
containing 79% xenon and 21% oxygen, with a flow rate of
10 L.min21. Following initial saturation of the breathing
circuit, the animals were ventilated for 20 minutes at a
constant 1-L.min21 flow rate. An additional variable flow
rate of O2 was used as needed to maintain the inspired
fraction of O2 at 21% according to the gas analyzer. The
Control group received room air ventilation at a flow rate of
1 L.min21 and additional O2 ventilation to maintain the
FiO2 at 21%. After data were collected at the 20-minute time
point, the configuration of the respiratory circuit was
changed from closed to open to allow for the rapid clearance
of xenon. The fresh gas flow was then adjusted to
10 L.min21 for both groups. The ventilatory settings were
kept constant throughout the experiment. After the end of
the experiment, the animals were euthanized by injecting
KCl (25 mEq.L21) intravenously and sent to the animal care
facility for adequate disposal.
Statistical analysis
The distribution of the data was tested for normality
using the Kolmogorov-Smirnov test. Weight, body surface
area and blood volume lost were compared between groups
using Student’s t-test for unpaired samples. The temporal
behavior of hemodynamic, respiratory, metabolic and
oxygen transport variables was evaluated using a two-way
analysis of variance for repeated measures, followed by a
Newman-Keuls post-hoc test when indicated. P-values less
than 0.05 were considered statistically significant. The
results are expressed as the mean ¡ standard deviation
(SD). All statistical analyses were performed using the
statistical packages Aabel 3.0.5 (Gigawiz Ltd. Co., Tulsa,
OK, USA) and G Power 3 (Heinrich-Heine-Universita¨t,
Dusseldorf, Germany).
& RESULTS
The Control and Experimental groups were similar with
respect to weight, BSA and blood volume losses, as
indicated in Table 1. The volume of blood removed was
44 mL.kg21 in the Control group and 40 mL.kg21 in the
Xenon group and the blood removal caused a significant
reduction in the cardiac index in both groups (64 and 67%,
respectively), measured immediately after shock (upper
panel of Figure 1). Following the shock induction phase, a
non-significant increase in the cardiac index was observed
that was similar in both groups. At 20 minutes post-blood
loss, the cardiac indexes were 33 and 42% lower than
baseline measurements in the control and Xenon groups,
respectively (p,0.05). The removal of xenon inhalation at 20
minutes post-shock did not alter the cardiac index. The
mean arterial pressure decreased in both groups by 55%
following the blood loss phase compared with baseline
values. These values remained stable throughout the
remainder of the experiment (lower panel of Figure 1). As
seen in Table 2, there was a significant and persistent
increase in heart rate and pulmonary vascular resistance
index after shock that was similar in both groups. The
systemic vascular resistance index transiently increased
after shock, returning to baseline levels during the observa-
tion period, but there was no significant difference between
the groups. The mean pulmonary arterial pressure, cardiac
filling pressures and left and right ventricular systolic
work indexes exhibited a marked reduction until the last
measurement was taken. The interruption of xenon inhalation
did not produce any significant alterations or improvement in
hemodynamics compared with measurements taken at the 20-
minute time point.
Table 2 - Hemodynamic behavior of the animals in the Control and Xenon groups during the study.
Group Baseline After shock 5 min 20 min 40 min p-value
HR (bpm) Control 75 ¡ 19 123 ¡ 38* 124 ¡ 37* 133 ¡ 31* 140 ¡ 28* NS
Xenon 73 ¡ 18 137 ¡ 32* 139 ¡ 34* 149 ¡ 35* 142 ¡ 35*
CVP (mmHg) Control 7 ¡ 2 3 ¡ 1* 3 ¡ 1* 3 ¡ 1* 3 ¡ 1* NS
Xenon 7 ¡ 1 3 ¡ 1* 3 ¡ 1* 4 ¡ 1* 3 ¡ 2*
mPAP (mmHg) Control 18 ¡ 3 10 ¡ 3*! 11 ¡ 2*! 11 ¡ 3*! 14 ¡ 3* NS
Xenon 17 ¡ 4 9 ¡ 2*! 11 ¡ 3*! 12 ¡ 3*! 13 ¡ 4*
POAP (mmHg) Control 11 ¡ 3 5 ¡ 2* 5 ¡ 2* 4 ¡ 2* 6 ¡ 2* NS
Xenon 10 ¡ 2 4 ¡ 2* 5 ¡ 2* 6 ¡ 3* 5 ¡ 2*
SVRi (dyne.s.cm25.m22) Control 7067 ¡ 1675 9924 ¡ 4464* 6651 ¡ 2723 5574 ¡ 2156 6080 ¡ 1971 NS
Xenon 6108 ¡ 1565 8202 ¡ 3298* 6206 ¡ 2311 5659 ¡ 1571 5370 ¡ 1935
PVRi (dyne.s.cm25.m22) Control 366 ¡ 97 676 ¡ 332* 553 ¡ 161* 553 ¡ 232* 729 ¡ 478* NS
Xenon 304 ¡ 158 672 ¡ 246* 629 ¡ 244* 502 ¡ 228* 594 ¡ 289*
LVSWi (g?m.m22) Control 45.8 ¡ 11.8 5.3 ¡ 5.3* 8.5 ¡ 7.9* 9.8 ¡ 7.6* 10.3 ¡ 7.5* NS
Xenon 43.4 ¡ 11.8 3.7 ¡ 2.7* 4.8 ¡ 3.4* 7.5 ¡ 5.2* 9.3 ¡ 4.3*
RVSWi (g?m.m22) Control 5.6 ¡ 1.4 0.7 ¡ 0.7* 1.3 ¡ 1* 1.4 ¡ 0.9* 1.5 ¡ 1* NS
Xenon 5.5 ¡ 2.1 0.5 ¡ 0.3* 0.8 ¡ 0.4* 1.1 ¡ 0.6* 1.5 ¡ 0.7*
HR – heart rate; CVP – central venous pressure; mPAP – mean pulmonary artery pressure; PAOP – pulmonary artery occlusion pressure; SVRi – systemic
vascular resistance index; PVRi – pulmonary vascular resistance index; LVSWi – left ventricular systolic work index; RVSWi – right ventricular systolic work
index. * indicates a difference from baseline, p ¡ 0.05. ! indicates a difference at the 40-min time point, p,0.05. NS indicates no significant difference.
Data are expressed as the mean ¡ SD. n= 13 for both the Control and Xenon groups.
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The induction of shock promoted a significant and
progressive increase in lactate levels compared with the
baseline levels that was similar in both groups (upper panel
of Figure 2). The mixed central venous saturation decreased
from 69 and 67% to 23 and 24% in the Control and Xenon
groups, respectively. Saturation remained low in both
groups through the end of the study (middle panel of
Figure 2). The veno-arterial CO2 difference increased four-
fold in both groups compared with baseline values and
remained elevated throughout the study (lower panel of
Figure 2). As noted in Table 3, there was a similar and
significant four-fold reduction in oxygen delivery, accom-
panied by an important and sustained augmentation of the
oxygen extraction rate, from 29 and 30% to 76 and 74% in
the Control and Xenon groups, respectively. The initiation
of shock induced a significant decrease in arterial pH,
arterial base excess and bicarbonate concentrations that
were similar in both groups (Table 3). The removal of xenon
from the respiratory mixture did not result in any changes
in tissue perfusion markers. No changes in other metabolic
parameters were observed. Hemoglobin levels did not
change throughout the study, as shown in Table 3.
Table 4 shows the values of the gas exchange and
respiratory mechanics variables observed during the study.
As seen in the table, none of the studied variables were
affected by the induction of shock or the initiation or
cessation of xenon inhalation.
& DISCUSSION
In this study, we observed that xenon inhalational
anesthesia did not decrease hemodynamic variables or
tissue perfusion markers in dogs experiencing severe
hemorrhagic shock. Gas exchange and respiratory
mechanics were not affected by the initiation of inhaled
xenon. In addition, the removal of xenon from the
respiratory mixture did not produce any improvement in
systemic hemodynamics or tissue perfusion.
The properties of xenon anesthesia have been well
established (3). The gas has been shown to cause minimal
to no cardiovascular instability in experimental and clinical
studies in healthy subjects (15,16). Luttropp et al. studied
the effects of xenon anesthesia (65% xenon in oxygen) on
myocardial function. In their study, the cerebral blood flow
velocities in 17 ASA 1 patients undergoing open abdominal
surgery were investigated using transesophageal echocar-
diography and transcranial Doppler sonography (17). The
authors did not observe any adverse effects of xenon
anesthesia on myocardial function. However, they observed
increased blood flow in cerebral arteries 15 and 30 minutes
after the inhalation of xenon. Recently, a multicenter study
was conducted to investigate left ventricular function
during anesthesia with xenon compared with isoflurane.
Using transesophageal echocardiography, 252 patients were
evaluated. It was observed that xenon did not reduce
contractility; however, isoflurane did decrease the contrac-
tile index in patients even in the absence of cardiac
dysfunction (18). Even in patients with heart failure under-
going implantation of a cardioverter-defibrillator, xenon use
during anesthesia has been proven to better maintain mean
arterial pressure and the left ventricular ejection fraction
compared with propofol/remifentanil anesthesia (10). In
recent years, several other studies have been published that
have associated xenon inhalation with cardiac precondition-
ing and myocardial protection in patients with ischemia and
myocardial infarction (8,19-22).
Despite the many studies that have been conducted on the
hemodynamic safety profile of xenon anesthesia in healthy
subjects and those with cardiac dysfunction, very few
studies have tested the impact of xenon on hemodynamic
stability and tissue perfusion in the context of severe
hemorrhagic shock. Baumert et al. investigated the hemo-
dynamic variables in pigs anesthetized with xenon/remi-
fentanil or isoflurane/remifentanil and subjected to
hemorrhagic shock (20 mL.kg21 bleeding volume), followed
Figure 2 - The arterial lactate (upper panel), mixed venous
saturation (middle panel) and venous-arterial CO2 (lower panel)
differences between the Control (open circles; n= 13) and Xenon
(closed circles; n =13) groups during the study. * indicates a
significant difference from baseline, p,0.05. NS indicates no
significant difference. The x-axes of the graphs are not linear, so
the curves are not true to scale. Data are expressed as the
mean¡SD.
Xenon anesthesia in dogs undergoing shock
Franceschi RC et al.
CLINICS 2013;68(2):231-237
234
by reinfusion (12). These authors observed that the
hemodynamic response to acute hemorrhage appeared
faster and was more severe with xenon/remifentanil than
with isoflurane/remifentanil anesthesia. Despite the fact
that the model we used in this study was different from that
used by Baumert et al., our results point in the opposite
direction of their observations. In our study, the hemor-
rhagic shock was more profound and the bleeding volume
was 44 mL.kg21 in the Control group and 40 mL.kg21 in the
Xenon group, corresponding to 46 and 42% of the total
blood volume, respectively (23). Second, the maximum
possible concentration of xenon (inhalation of 79% Xe in
room air) was selected to elicit the maximum hemodynamic
interference during severe shock conditions. Finally,
because our objective was to evaluate the impact of xenon
anesthesia during shock, we did not test the hemodynamic
behavior of other inhalational anesthetics.
In the Experimental group, xenon anesthesia was intro-
duced when the dogs were in shock and it did not induce
any further deterioration in hemodynamics or tissue
oxygenation compared with the Control group. One
possible explanation for this absence of hemodynamic
interference is that the actual autonomic nervous system
activity was preserved during xenon inhalation. This is
suggested by the absence of a difference in heart rate and
either pulmonary or systemic vascular resistance between
the groups. According to Baumert et al., autonomic beat-to-
beat HR modulation was better preserved with xenon-based
anesthesia than with propofol-based anesthesia (9). The
authors believe this was a result of xenon’s limited effects on
Table 4 - Values of the gas exchange and respiratory mechanics variables during the study in the Control and Xenon
groups.
Group Baseline After shock 5 min 20 min 40 min p-value
PaO2 (mmHg) Control 97 ¡ 16 110 ¡ 16 98 ¡ 15 94 ¡ 11 99 ¡ 14 NS
Xenon 91 ¡ 7 108 ¡ 18 103 ¡ 15 103 ¡ 14 87 ¡ 9
PaCO2 (mmHg) Control 33 ¡ 3 23 ¡ 5 29 ¡ 7 33 ¡ 7 34 ¡ 7 NS
Xenon 34 ¡ 4 28 ¡ 4 31 ¡ 5 34 ¡ 5 34 ¡ 5
ETCO2 (mmHg) Control 30 ¡ 3 18 ¡ 4 19 ¡ 8 22 ¡ 9 24 ¡ 10 NS
Xenon 29 ¡ 10 17 ¡ 6 23 ¡ 4 24 ¡ 7 29 ¡ 5
GAaO2 (mmHg) Control 10.8 ¡ 9.3 9.4 ¡ 9.9 13.7 ¡ 11.3 12 ¡ 8.7 8.7 ¡ 7.7 NS
Xenon 12.8 ¡ 7.8 10.2 ¡ 15.9 6.9 ¡ 5.3 6.8 ¡ 5.6 15.4 ¡ 7.2
Shunt (%) Control 11.4 ¡ 5.4 3.3 ¡ 2.2 6.5 ¡ 3.9 7.8 ¡ 3.5 7.5 ¡ 4.3 NS
Xenon 15.8 ¡ 11.8 4.5 ¡ 5.2 5.6 ¡ 3.5 6.5 ¡ 4.8 9.7 ¡ 4.3
Peak pressure (cmH2O) Control 13.5 ¡ 2.4 14.3 ¡ 1.3 14.8 ¡ 2.7 15.5 ¡ 2.6 14.7 ¡ 2.4 NS
Xenon 12.6 ¡ 1.2 15.1 ¡ 2.8 15.6 ¡ 1.6 15.3 ¡ 2.3 14.6 ¡ 2.1
Plateau pressure (cmH2O) Control 14.3 ¡ 5.4 14.6 ¡ 5.1 15 ¡ 5.3 14.3 ¡ 2.6 15.3 ¡ 4.9 NS
Xenon 11.6 ¡ 0.9 14 ¡ 2.5 14.3 ¡ 1.7 15.4 ¡ 5.2 13.8 ¡ 2.3
PEEP (cmH2O) Control 1.7 ¡ 0.7 1.6 ¡ 0.6 1.8 ¡ 0.6 1.6 ¡ 0.7 1.9 ¡ 0.6 NS
Xenon 1.7 ¡ 0.4 1.5 ¡ 0.6 1.9 ¡ 0.4 2 ¡ 0.6 1.5 ¡ 0.6
VTexp (mL) Control 278 ¡ 44 274 ¡ 39 275 ¡ 42 285 ¡ 64 285 ¡ 39 NS
Xenon 282 ¡ 51 290 ¡ 53 305 ¡ 67 304 ¡ 76 279 ¡ 53
Cstat (cmH2O.L
21) Control 46 ¡ 21 48 ¡ 18 49 ¡ 20 46 ¡ 15 48 ¡ 18 NS
Xenon 36 ¡ 8 45 ¡ 16 43 ¡ 13 46 ¡ 21 46 ¡ 15
ETCO2 – end-tidal CO2; GAaO2 – alveolar-arterial oxygen gradient; VTexp – expired tidal volume; Cstat – static compliance of the respiratory system. NS
indicates no significant difference. Data are expressed as the mean ¡ SD. n= 13 for both the Control and Xenon groups.
Table 3 - Values of the metabolic, hemoglobin and oxygen transport variables during the study in the Control and
Xenon groups.
Group Baseline After shock 5 min 20 min 40 min p-value
Arterial pH Control 7.36 ¡ 0.05 7.39 ¡ 0.09 7.26 ¡ 0.09* 7.15 ¡ 0.11* 7.15 ¡ 0.11* NS
Xenon 7.35 ¡ 0.08 7.35 ¡ 0.08 7.2 ¡ 0.1* 7.19 ¡ 0.08* 7.15 ¡ 0.06*
Arterial HCO3 Control 18.1 ¡ 1.4 13.7 ¡ 1.9* 12.5 ¡ 1.8* 11.7 ¡ 2.6*! 11.8 ¡ 3.8*! NS
(mmol.L21) Xenon 19.2 ¡ 2.2 14.6 ¡ 3* 12.2 ¡ 3.2* 12.6 ¡ 2.5*! 11.8 ¡ 2.2*!
Arterial base excess Control -5.5 ¡ 2.1 -9 ¡ 2.7 -13 ¡ 3 -16.3 ¡ 4.7 -13.7 ¡ 5.8 NS
(mmol.L21) Xenon -4.6 ¡ 2.6 -9.1 ¡ 4.2 -14.6 ¡ 5 -14.6 ¡ 4 -16 ¡ 3.3
Hemoglobin Control 12.3 ¡ 1.8 11.4 ¡ 1.8 11.1 ¡ 1.9 10.4 ¡ 1.9 10.3 ¡ 2.1 NS
(g.dL21) Xenon 11.6 ¡ 2.2 11.6 ¡ 2.5 10.6 ¡ 1.8 10.7 ¡ 1.7 10.7 ¡ 1.7
DO2i Control 266 ¡ 54 88 ¡ 38 125 ¡ 46 147 ¡ 66 151 ¡ 78 NS
(mL.min21.m22) Xenon 265 ¡ 85 86 ¡ 23 102 ¡ 33 140 ¡ 47 158 ¡ 45
VO2i Control 75 ¡ 22 67 ¡ 33 89 ¡ 34 107 ¡ 34 93 ¡ 40 NS
(mL.min21.m22) Xenon 72 ¡ 34 63 ¡ 22 78 ¡ 26 94 ¡ 30 117 ¡ 36
O2ER Control 29 ¡ 10 76 ¡ 14 75 ¡ 14 76 ¡ 12 69 ¡ 19 NS
(%) Xenon 3 ¡ 16 74 ¡ 2 77 ¡ 14 70 ¡ 17 75 ¡ 14
DO2i – systemic oxygen delivery; VO2i – systemic oxygen consumption; O2ER – oxygen extraction rate; * indicates a difference from baseline, p,0.05.
! indicates a difference from the value immediately after shock, p,0.05. NS indicates no significant difference. The data are expressed as the mean¡ SD.
n= 13 for both the Control and Xenon groups.
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sympathetic-vagal activity (12). On the other hand, Hanss
et al. showed that xenon increased parasympathetic activity
and decreased sympathetic activity, in contrast to the effects
of total intravenous anesthesia (24). Marx et al. observed
that plasma adrenaline concentrations were decreased in
pigs anesthetized with xenon anesthesia compared with the
Control group, a finding that is potentially explained by the
analgesic properties of xenon. Although adrenaline concen-
trations were decreased, circulating catecholamines
remained at normal levels (25). Based on these studies and
our results, we hypothesize that in subjects submitted to
circulatory shock, the minimal sympathetic inhibition
induced by xenon in high inspiratory concentrations is not
capable of offsetting the intense autonomic response to the
shock. Therefore, hemodynamic variables and tissue perfu-
sion were not negatively affected by the administration of
xenon.
A second point that may also contribute to the well-
tolerated hemodynamic profile of xenon during shock is
that xenon inhalation does not hamper myocardial contrac-
tility or its response to inotropic stimuli (18). Using isolated
guinea pig ventricular muscle bundles, Schroth et al.
observed that, in contrast to isoflurane, xenon did not alter
the force of myocardial contractions or their response to
inotropic stimuli, such as calcium, isoproterenol and
increased pacing frequency (15). As described above,
several other authors also described the absence of
significant effects of xenon on myocardial contractility in
either experimental or clinical contexts (7,17,26).
Experimentally, xenon has a minimal impact on autonomic
nervous system activity and myocardial function, making it
a suitable choice for general anesthesia in subjects in shock.
An important point about this study is that splenectomy
was not performed to simulate a real trauma situation, in
which patients with shock are immediately transported to
the operating room to undergo damage control surgery (27).
As a consequence, there was a partial recovery in mean
artery pressure values within the 1 to 2 minutes necessary to
collect blood samples for laboratory analysis and perform
hemodynamic measurements after interrupting blood with-
drawal. As the magnitude of shock was comparable in both
groups, as can be observed from the similar MAP values
after shock and blood volume removed (Control group,
40 mL.kg21; Experimental group, 44 mL.kg21), this partial
recovery of MAP values does not alter the results of the
study.
In conclusion, the use of xenon at the maximum inhaled
concentration in a canine model of severe hemorrhagic
shock did not promote a decrease in hemodynamic stability,
oxygen transport or tissue perfusion. However, clinical
studies are necessary to confirm the applicability of xenon-
based anesthesia in hemorrhagic shock patients.
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